MIM
TCRT icon

MetLife Investment Management’s Alaunos Therapeutics TCRT Stock Holding History

MetLife Investment Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-81
Closed -$13.2K – 2770
2021
Q4 		$13.2K Sell
81
-441
-84% -$96.9K ﹤0.01% 2491
2021
Q3 		$142K Buy
522
+236
+83% +$72.2K ﹤0.01% 2275
2021
Q2 		$113K Sell
286
-283
-50% -$132K ﹤0.01% 2398
2021
Q1 		$307K Buy
569
+173
+44% +$108K ﹤0.01% 1799
2020
Q4 		$150K Sell
396
-47
-11% -$18.7K ﹤0.01% 2129
2020
Q3 		$168K Sell
443
-209
-32% -$92.3K ﹤0.01% 1963
2020
Q2 		$321K Buy
652
+90
+16% +$40.1K ﹤0.01% 1622
2020
Q1 		$207K Buy
562
+189
+51% +$97.8K ﹤0.01% 1680
2019
Q4 		$264K Sell
373
-127
-25% -$87.4K ﹤0.01% 1826
2019
Q3 		$321K Hold
500
– – ﹤0.01% 1666
2019
Q2 		$437K Buy
500
+71
+17% +$48.8K ﹤0.01% 1562
2019
Q1 		$248K Hold
429
– – ﹤0.01% 1861
2018
Q4 		$120K Hold
429
– – ﹤0.01% 2203
2018
Q3 		$206K Sell
429
-11
-3% -$4.72K ﹤0.01% 2062
2018
Q2 		$199K Buy
440
+192
+77% +$122K ﹤0.01% 1922
2018
Q1 		$146K Sell
248
-161
-39% -$100K ﹤0.01% 2050
2017
Q4 		$254K Buy
+409
New +$294K ﹤0.01% 1803

Other funds holding TCRT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

MetLife Investment Management's TCRT Position: Q1 2022 in Review

MetLife Investment Management sold out of Alaunos Therapeutics (TCRT) in Q1 2022, closing a stake of 81 shares — an estimated $13.2K sold.

MetLife Investment Management first reported a position in TCRT in Q4 2017 and held it in 17 quarters. The position peaked at $437K in Q2 2019. 148 funds tracked by Wall St. Rank hold TCRT as of Q1 2022.

  • MetLife Investment Management reported no remaining Alaunos Therapeutics position as of Q1 2022 after selling out during the quarter.
  • MetLife Investment Management sold 81 Alaunos Therapeutics shares in Q1 2022, an estimated $13.2K.
  • MetLife Investment Management first reported a position in Alaunos Therapeutics in Q4 2017 and held it in 17 quarters.
  • MetLife Investment Management's Alaunos Therapeutics position peaked at $437K in Q2 2019.
  • 148 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2022.

Based on MetLife Investment Management's 13F filing for Q1 2022, filed 12 May 2022.